The Conferencing Zone

Conferencing Industry News Article

TMCNet: Issues Investment Alert On (OTC:MCLN), (OTC:BGNN), (OTC:SCRA), (OTC:CTIX), (AMEX:VRNG)

[December 27, 2012] Issues Investment Alert On (OTC:MCLN), (OTC:BGNN), (OTC:SCRA), (OTC:CTIX), (AMEX:VRNG)

POMPANO BEACH, FL, Dec 27, 2012 ( via COMTEX) MedClean Technologies Inc (OTC:MCLN) declined 50% to $0.0001 at a traded volume of 1.50 million shares. The Company designs and manufactures onsite regulated medical waste processing systems. The Company offers MedClean System that enables hospitals and other healthcare providers to convert bio-hazardous regulated medical waste into sterile unrecognizable material suitable for disposal as municipal solid waste. The Price/Sale ratio of the Company is 0.59.

Will MCLN Move Higher After Today's Sudden Selling Activities Don't Miss The Free Trend Analysis here company=MCLN B Green Innovations, Inc(OTC:BGNN) is currently trading at $0.0004 at a traded volume of 1.25 million shares. The Company focuses on acquiring and identifying technologies that address environmental issues. The company also supports the interactive voice response software, which is designed to read information from and write information to databases, as well as to query databases and return information. The Price/Sale ratio of the Company is 0.94.

How Should Investors Trade BGNN After The Recent Momentum, Find Out Here company=BGNN SecureAlert Inc (OTC:SCRA) declined 1.93% to $0.0711 at a traded volume of 1.19 million shares. The Market Cap of the Company is 43.98 million. The 52 week range of the stock is 0.01 to 0.08. The Company has specialized in electronic monitoring of offenders including pretrial, probation and parole.

Get Free Special Trend Analysis On SCRA Here company=SCRA CellceutixCorp(OTC:CTIX) declined 8.68% to $2.21 at a traded volume of 1.52 million shares. The Company provides commentary on a front page New York Times article published December 23, 2012 titled, "Genetic Gamble; New Approaches to Fighting Cancer."The Company is a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases.

The Company said that its clinical trials of its flagship anti-cancer drug Kevetrin have advanced to the next cohort.

Get Free Special Trend Analysis On CTIX Here company=CTIX Vringo, Inc (NYSEAMEX:VRNG) declined 3.11% to $2.80 at a traded volume of 1.04 million shares. The Market Cap of the Company is 224.92 million. The Company develops and provides software products for mobile video entertainment, personalization, and mobile social applications. The Price/Sale ratio of the Company is 872.74 and Price/Book ratio is 2.08. The 50-Day Moving Average and 200-Day Moving Average of the Company is 3.34 and 3.58 respectively.

Get Free Special Trend Analysis On VRNG Here company=VRNG About has a finger on the pulse of many sectors including renewable energy, oil, pharma, mining, finance, and healthcare. Our in depth research and analysis of NASDAQ, OTCBB, Pink Sheets, and NYSE has yielded considerable gains for our subscribers.

Our to-the-minute reports and alerts coupled with breaking news, analysis, investment strategies, and FREE subscription email services contribute to our role as one of the leading investor relations marketing firms.

Disclaimer: The assembled information disseminated by is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. does expect that investors will buy and sell securities based on information assembled and presented in PLEASE always do your own due diligence, and consult your financial advisor.

Contact: Pacific Dynasty Consultants Inc.

2637 E Atlantic Blvd #22611 Pompano Beach, FL 33062323-287-5171 SOURCE Associated Documentation:Link to submission on http://www.eteligis.comCSRNewsDaily.com_12-27-2012_SMU_2.docx

[ Back To Homepage ]


Featured Whitepaper

Basic Principles of Audio
Design in Conferencing

Basic Principles of Audio Design in Conferencing

The challenging duty of the sales person, engineer, or consultant, is to use scientific knowledge and previous practice to try to create a pleasant experience for all end users.

Featured Podcast

How often have you had a teleconference where—because of audio-related issues—you had difficulty in conducting an important meeting? Or in some cases, not even being able to make a clear connection at all? Curtiss Singleton, Director of Sales for the Americas at Revolabs, Inc., discusses conferencing solutions that not only provide unmatched audio quality, but ones that also “cut the cord”—giving you the freedom to move around the workspace. Doug Green, Publisher of Telecom Reseller, speaks with JP Carney, President and CEO of Revolabs, about the company, the importance of audio quality in UC, the compatibility of their products with various UC platforms, and their acquisition by Yamaha after one year. They discuss how clear audio for teleconferencing is the core element of true collaboration.

Featured Blog